Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Competitive inhibitors of trypsin-like proteases in development at AstraZeneca

July 8, 1999

Eptifibatide authorized for marketing in all E.U. member states

July 7, 1999

SmithKline Beecham and Fournier enter agreement for new antithrombotic

July 7, 1999

New cardiovascular disease candidate from Merck KGaA enters phase II

July 6, 1999

Novel glycoside antithrombotic agents in the pipeline at Gedeon Richter

July 6, 1999

Pharming begins phase I development of human lactoferrin

July 5, 1999

DuPont files NDA for Innohep for treatment and prevention of deep vein thrombosis

July 2, 1999

Corvas presents novel peptide aldehydes as thrombin inhibitors

July 1, 1999

Roberts buys rights to Agrylin from Bristol-Myers Squibb

June 29, 1999

One-year NINDS study results on t-PA for acute ischemic stroke

June 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...